← Back to headlines
CRISPR (CRSP) Receives 'Overweight' Rating Amid Gene Editing Growth
CRISPR Therapeutics (CRSP) has been rated 'Overweight' by analysts, reflecting positive sentiment regarding the company's growth prospects in gene editing.
31 Mar, 08:46 — 31 Mar, 08:46
Sources
Showing 1 of 1 sources
